{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:10:11Z","timestamp":1790021411854,"version":"4.0.1"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.sleep.2026.108792","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:04:17Z","timestamp":1769011457000},"page":"108792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The effect of Dual Orexin Receptor Antagonists on sleep: a systematic review and pairwise meta-analysis"],"prefix":"10.1016","volume":"140","author":[{"given":"Anastasios","family":"Stefanou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Boskou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas S.","family":"Lappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios Panteleimon","family":"Bozikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-5091","authenticated-orcid":false,"given":"Myrto T.","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2026.108792_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18782","article-title":"Incidence, persistence, and remission rates of insomnia over 5 years","volume":"3","author":"Morin","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2026.108792_bib2","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.sleep.2026.108792_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291859","article-title":"Incidence of adverse cardiovascular events in patients with insomnia: a systematic review and meta-analysis of real-world data","volume":"18","author":"Ali","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.sleep.2026.108792_bib4","series-title":"Sleep disorders affect cardiovascular health (Factsheet)","year":"2023"},{"key":"10.1016\/j.sleep.2026.108792_bib5","doi-asserted-by":"crossref","unstructured":"Chen, Y., Tong, E., Rao, Y., Yu, E.Y., Zeegers, M., Wesselius, A., n.d. The association between insomnia (related symptoms) and glycaemic control: a systematic review and meta-analysis. J Glob Health 15, 04016. https:\/\/doi.org\/10.7189\/jogh.15.04016.","DOI":"10.7189\/jogh.15.04016"},{"key":"10.1016\/j.sleep.2026.108792_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.635564","article-title":"Sleep duration and the risk of metabolic syndrome in adults: a systematic review and meta-analysis","volume":"12","author":"Hua","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.sleep.2026.108792_bib7","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/sleep\/26.8.986","article-title":"Total sleep deprivation elevates blood pressure through arterial baroreflex resetting: a study with microneurographic technique","volume":"26","author":"Ogawa","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2047487312460020","article-title":"Insomnia and risk of cardiovascular disease: a meta-analysis","volume":"21","author":"Sofi","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.sleep.2026.108792_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111899","article-title":"Sleep disorders and Alzheimer's disease pathophysiology: the role of the glymphatic system. A scoping review","volume":"217","author":"Astara","year":"2024","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.sleep.2026.108792_bib10","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/jcmm.14170","article-title":"Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment","volume":"23","author":"Fang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.sleep.2026.108792_bib11","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ncl.2012.08.018","article-title":"Psychiatric disorders and sleep","volume":"30","author":"Krystal","year":"2012","journal-title":"Neurol Clin"},{"key":"10.1016\/j.sleep.2026.108792_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-019-0478-5","article-title":"Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors","volume":"45","author":"Wang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.sleep.2026.108792_bib13","series-title":"Sleep disorders medicine: basic science, technical considerations and clinical aspects","first-page":"475","article-title":"International classification of sleep disorders","author":"Thorpy","year":"2017"},{"key":"10.1016\/j.sleep.2026.108792_bib14","series-title":"International classification of diseases","year":"2019"},{"key":"10.1016\/j.sleep.2026.108792_bib15","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.sleep.2026.108792_bib16","first-page":"1049","article-title":"National institutes of health state of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005","volume":"28","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(22)01322-8","article-title":"What is the right drug for insomnia disorder?","volume":"400","author":"Samara","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.sleep.2026.108792_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis","volume":"400","author":"De Crescenzo","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.sleep.2026.108792_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13181-013-0294-y","article-title":"In the zzz zone: the effects of Z-Drugs on human performance and driving","volume":"9","author":"Gunja","year":"2013","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.sleep.2026.108792_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/phar.2170","article-title":"Association between development of dementia and use of benzodiazepines: a systematic review and meta-analysis","volume":"38","author":"Lucchetta","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.sleep.2026.108792_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/M15-2175","article-title":"Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sleep.2026.108792_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14035","article-title":"The european insomnia guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib24","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11606-018-4390-1","article-title":"Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review","volume":"33","author":"Koffel","year":"2018","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.sleep.2026.108792_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsmc.2020.11.002","article-title":"Adherence to cognitive behavior therapy for insomnia: an updated systematic review","volume":"16","author":"Agnew","year":"2021","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.sleep.2026.108792_bib26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1017\/S1352465822000571","article-title":"ACT-i, an insomnia intervention for autistic adults: a pilot study","volume":"51","author":"Lawson","year":"2023","journal-title":"Behav Cognit Psychother"},{"key":"10.1016\/j.sleep.2026.108792_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.sleep.2024.08.011","article-title":"Experiences of and treatment preferences for insomnia in autistic adults: an interpretative phenomenological analysis","volume":"122","author":"Nijhof","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smrv.2017.02.001","article-title":"Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis","volume":"38","author":"van Straten","year":"2018","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2026.108792_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.smrv.2013.01.001","article-title":"Adherence to cognitive behavioral therapy for insomnia: a systematic review","volume":"17","author":"Matthews","year":"2013","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2026.108792_bib30","series-title":"Belsombra","author":"Sharp","year":"2014"},{"key":"10.1016\/j.sleep.2026.108792_bib33","series-title":"New Oxford textbook of psychiatry","author":"Geddes","year":"2020"},{"key":"10.1016\/j.sleep.2026.108792_bib34","series-title":"Neuroscientific Basis and practical Applications","article-title":"Stahl's essential psychopharmacology","author":"Stahl","year":"2021"},{"key":"10.1016\/j.sleep.2026.108792_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0000000000000425","article-title":"Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Albadrani","year":"2023","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1070522","article-title":"Dual orexin receptor antagonists for treatment of insomnia: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant","volume":"13","author":"Khazaie","year":"2022","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2026.108792_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad293","article-title":"Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis","volume":"47","author":"Na","year":"2024","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-023-01859-8","article-title":"The comparative effectiveness and safety of insomnia drugs: a systematic review and network meta-analysis of 153 randomized trials","volume":"83","author":"Pan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2026.108792_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-0043-1768667","article-title":"Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis","volume":"81","author":"Rocha","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.sleep.2026.108792_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101573","article-title":"The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis","volume":"61","author":"Xue","year":"2022","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2026.108792_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.sleep.2026.108792_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.sleep.2026.108792_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.sleep.2026.108792_bib44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and Mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.sleep.2026.108792_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.sleep.2026.108792_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The leeds sleep evaluation questionnaire in psychopharmacological investigations\u2014a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.sleep.2026.108792_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","article-title":"Quantification of sleepiness: a new approach","volume":"10","author":"Hoddes","year":"1973","journal-title":"Psychophysiology"},{"key":"10.1016\/j.sleep.2026.108792_bib48","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib49","series-title":"R: a Language and environment for statistical computing","year":"2024"},{"key":"10.1016\/j.sleep.2026.108792_bib50","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-Effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Glob Spine J"},{"key":"10.1016\/j.sleep.2026.108792_bib51","series-title":"Cochrane handbook for systematic reviews of interventions","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2024"},{"key":"10.1016\/j.sleep.2026.108792_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"key":"10.1016\/j.sleep.2026.108792_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.sleep.2026.108792_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.sleep.2026.108792_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.sleep.2026.108792_bib56","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.sleep.2026.108792_bib57","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5.1","article-title":"Chapter 14: completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2024"},{"key":"10.1016\/j.sleep.2026.108792_bib58","series-title":"DREAM: a double-blind, CrossoveR, placebo-controlled Study to compare the Effects of Nighttime Administration of suvorexant in patients with Multiple Sclerosis fatigue and insomnia","author":"Brown","year":"2025"},{"key":"10.1016\/j.sleep.2026.108792_bib59","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1212\/WNL.0000000000208595","article-title":"A randomized, double-blind, placebo-controlled pilot Study of suvorexant for insomnia in parkinson disease (P11-5.005)","volume":"104","author":"Burdick","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2026.108792_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.sleep.2026.108792_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14334","article-title":"Respiratory safety of lemborexant in adult and elderly subjects with moderate-to-severe chronic obstructive pulmonary disease","volume":"34","author":"Cheng","year":"2025","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib62","first-page":"57","article-title":"A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea","volume":"20","author":"Cheng","year":"2024","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13021","article-title":"Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double-blind, placebo-controlled, crossover study","volume":"29","author":"Cheng","year":"2020","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib64","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ijnp\/pyx033","article-title":"Phase II proof-of-concept trial of the orexin receptor antagonist Filorexant (MK-6096) in patients with major depressive disorder","volume":"20","author":"Connor","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib65","doi-asserted-by":"crossref","first-page":"pyw022","DOI":"10.1093\/ijnp\/pyw022","article-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist Filorexant (MK-6096) in patients with primary insomnia","volume":"19","author":"Connor","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2026.108792_bib67","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/0269881118773745","article-title":"A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity","volume":"32","author":"De Boer","year":"2018","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.sleep.2026.108792_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/AJP.0000000000000503","article-title":"Orexin receptor antagonism in painful diabetic neuropathy: a phase 2 trial with filorexant","volume":"34","author":"Herring","year":"2018","journal-title":"Clin J Pain"},{"key":"10.1016\/j.sleep.2026.108792_bib69","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2026.108792_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn8238","article-title":"Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper","volume":"14","author":"Huhn","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.sleep.2026.108792_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.70002","article-title":"A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia","author":"Lederer","year":"2025","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib73","article-title":"Phase 1b\/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: a randomized controlled trial","volume":"14","author":"Martin","year":"2025","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.sleep.2026.108792_bib74","article-title":"Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study","volume":"2","author":"Mayleben","year":"2021","journal-title":"Sleep Adv J Sleep Res Soc"},{"key":"10.1016\/j.sleep.2026.108792_bib75","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jamapsychiatry.2025.1999","article-title":"Efficacy and safety of seltorexant in insomnia disorder: a randomized clinical trial","volume":"82","author":"Mesens","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2026.108792_bib78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2026.108792_bib79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14283\/jpad.2020.69","article-title":"Safety and efficacy of lemborexant in patients with irregular sleep-wake rhythm disorder and alzheimer's disease dementia: results from a phase 2 randomized clinical trial","volume":"8","author":"Moline","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.sleep.2026.108792_bib80","first-page":"765","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening","volume":"16","author":"Murphy","year":"2020","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib81","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.2147\/DDDT.S501111","article-title":"Pharmacokinetics, pharmacodynamic, safety and tolerability of fazamorexant, a novel dual orexin receptor antagonist: report of the first-in-human study","volume":"19","author":"Ni","year":"2025","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.sleep.2026.108792_bib82","article-title":"Dual orexin receptor antagonists for delirium: a scoping review and feasibility trial of daridorexant","author":"Oldham","year":"2025","journal-title":"J Acad Consult-Liaison Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsac007","article-title":"A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women","volume":"45","author":"Rahman","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib84","first-page":"415","article-title":"Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo","volume":"16","author":"Roehrs","year":"2020","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and Zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2026.108792_bib86","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","article-title":"Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study","volume":"24","author":"Savitz","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib87","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.rmed.2014.12.010","article-title":"Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease","volume":"109","author":"Sun","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.sleep.2026.108792_bib88","series-title":"Presented at the society of biological psyhiatry annual meeting","article-title":"Seltorexant, adjunctive to antidepressants, in adults with major depressive disorder with insomnia symptoms: results of a double-blind, randomized, placebo-controlled study | NCT04533529","author":"Thase","year":"2025"},{"key":"10.1016\/j.sleep.2026.108792_bib89","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/jcph.523","article-title":"Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects","volume":"55","author":"Uemura","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsab224","article-title":"Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem","volume":"45","author":"Ufer","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sleep.2024.09.005","article-title":"Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled restless legs syndrome and persistent insomnia","volume":"124","author":"Winkelman","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib92","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/NSS.S434058","article-title":"Lack of efficacy of suvorexant in people with insomnia and poorly controlled type 2 diabetes","volume":"15","author":"Winkelman","year":"2023","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib93","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-018-0650-4","article-title":"Safety, tolerability, and pharmacokinetics of suvorexant: a randomized rising-dose trial in healthy men","volume":"38","author":"Yee","year":"2018","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.sleep.2026.108792_bib94","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2026.108792_bib95","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6614","article-title":"Effect of suvorexant vs placebo on total daytime sleep hours in shift workers","volume":"3","author":"Zeitzer","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2026.108792_bib96","doi-asserted-by":"crossref","first-page":"e970","DOI":"10.4088\/JCP.16m11194","article-title":"Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial","volume":"78","author":"Hatta","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib97","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.70033","article-title":"The effect of suvorexant on fear extinction recall: a double-blind randomised controlled pilot trial in healthy individuals","author":"Schenker","year":"2025","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib98","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1017\/S1092852924000336","article-title":"A double-blind, randomized, placebo-controlled plus open trial of adjunctive suvorexant for treatment-resistant insomnia in patients with bipolar disorder","volume":"29","author":"Cafaro","year":"2024","journal-title":"CNS Spectr"},{"key":"10.1016\/j.sleep.2026.108792_bib99","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1016\/j.sleep.2026.108792_bib100","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsac068","article-title":"Evaluation of suvorexant for trauma-related insomnia","volume":"45","author":"Mellman","year":"2022","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2026.108792_bib101","first-page":"41","article-title":"Efficacy and safety of suvorexant for the treatment of primary insomnia among Chinese: a 6-month randomized double-blind controlled study","volume":"22","author":"Fan","year":"2017","journal-title":"Neurol Asia"},{"key":"10.1016\/j.sleep.2026.108792_bib102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-Month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib103","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaf170","article-title":"Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial","volume":"48","author":"Huang","year":"2025","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib104","article-title":"A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder","volume":"139","author":"Mi","year":"2025","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib105","first-page":"1289","article-title":"Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.sleep.2024.07.037","article-title":"Daridorexant in Japanese patients with insomnia disorder: a phase 3, randomized, double-blind, placebo-controlled study","volume":"122","author":"Uchimura","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14302","article-title":"Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: results from phase 1 and 2 studies","volume":"34","author":"Uchiyama","year":"2025","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib108","article-title":"Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study","author":"Uchiyama","year":"2025","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib109","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.sleep.2026.108792_bib76","first-page":"1","article-title":"Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial","author":"Mesens","year":"2024","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.sleep.2026.108792_bib110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","article-title":"The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder","volume":"9","author":"Recourt","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146359","article-title":"Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder","volume":"1731","author":"Suchting","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.sleep.2026.108792_bib112","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.sleep.2021.11.015","article-title":"Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea","volume":"92","author":"Boof","year":"2022","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib113","first-page":"9","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib114","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13248","article-title":"Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease","volume":"30","author":"Boof","year":"2021","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27691","article-title":"Suvorexant for reduction of delirium in older adults after hospitalization: a randomized clinical trial","volume":"7","author":"Hatta","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2026.108792_bib116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40263-023-01055-y","article-title":"Treatment of sleep, motor and sensory symptoms with the orexin antagonist suvorexant in adults with idiopathic restless legs syndrome: a randomized double-blind crossover proof-of-concept study","volume":"38","author":"Garcia-Borreguero","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2026.108792_bib117","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40263-020-00768-8","article-title":"Pharmacological interactions between the dual orexin receptor antagonist daridorexant and ethanol in a double-blind, randomized, placebo-controlled, double-dummy, four-way crossover phase I study in healthy subjects","volume":"34","author":"Berger","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2026.108792_bib118","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bcpt.13930","article-title":"Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: randomized, double-blind, placebo-controlled phase-1 studies","volume":"133","author":"Kambe","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.sleep.2026.108792_bib119","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/02698811221080459","article-title":"Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: a randomized, placebo-controlled crossover study","volume":"36","author":"Landry","year":"2022","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.sleep.2026.108792_bib120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0000000000001561","article-title":"Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with Zolpidem and suvorexant in recreational sedative users","volume":"42","author":"Landry","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib121","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/02698811241293997","article-title":"Nighttime safety of daridorexant: evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function","volume":"39","author":"Magliocca","year":"2025","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.sleep.2026.108792_bib122","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/pcn.13888","article-title":"Driving performance in the morning after bedtime vornorexant administration: a randomized clinical trial using a driving simulator","volume":"79","author":"Miyazaki","year":"2025","journal-title":"Psychiatr Clin Neurosci"},{"key":"10.1016\/j.sleep.2026.108792_bib123","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cpt.2592","article-title":"Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator","volume":"111","author":"Muehlan","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.sleep.2026.108792_bib124","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40261-021-01062-1","article-title":"Impact of daridorexant, a dual orexin receptor antagonist, on cardiac repolarization following bedtime dosing: results from a thorough QT study using Concentration-QT analysis","volume":"41","author":"Schilling","year":"2021","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.sleep.2026.108792_bib125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/JCP.0000000000000516","article-title":"Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study","volume":"36","author":"Schoedel","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib126","doi-asserted-by":"crossref","first-page":"24353","DOI":"10.1073\/pnas.1907354116","article-title":"Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical\/cognitive functions after forced awakening","volume":"116","author":"Seol","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sleep.2026.108792_bib127","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.euroneuro.2016.07.002","article-title":"Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects","volume":"26","author":"Struyk","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib128","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy260","article-title":"On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers","volume":"42","author":"Vermeeren","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib129","first-page":"1803","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep J Sleep Sleep Disord Res"},{"key":"10.1016\/j.sleep.2026.108792_bib130","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa056.501","article-title":"Efficacy and safety of seltorexant in insomnia disorder","author":"Savitz","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.108792_bib131","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s12325-023-02489-y","article-title":"Summary of research: development and validation of the insomnia daytime symptoms and impacts questionnaire (IDSIQ)","volume":"40","author":"Hudgens","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.sleep.2026.108792_bib132","series-title":"Insomnia: psychological assessment and management","author":"Morin","year":"1993"},{"key":"10.1016\/j.sleep.2026.108792_bib133","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.sleep.2026.108792_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2022.101597","article-title":"Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis","volume":"62","author":"Hertenstein","year":"2022","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2026.108792_bib135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12888-016-1075-3","article-title":"Insomnia and the risk of depression: a meta-analysis of prospective cohort studies","volume":"16","author":"Li","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib136","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/16066359.2022.2074406","article-title":"Persistent sleep problems among people in recovery from substance use disorders: a mixed methods study","volume":"30","author":"Erga","year":"2022","journal-title":"Addiction Res Theor"},{"key":"10.1016\/j.sleep.2026.108792_bib137","first-page":"793","article-title":"Sleep disturbance in substance use disorders","volume":"38","author":"Roehrs","year":"2015","journal-title":"Psychiatr Clin"},{"key":"10.1016\/j.sleep.2026.108792_bib138","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41398-022-01897-y","article-title":"Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings","volume":"12","author":"Zhang","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.sleep.2026.108792_bib139","doi-asserted-by":"crossref","unstructured":"Yeh, W.-C., Li, Y.-S., Chang, Y.-P., Hsu, C.-Y., n.d. The efficacy and safety of dual orexin receptor antagonists in obstructive sleep apnea: a systematic review and meta-analysis of randomised controlled trials. J Sleep Res n\/a, e14399. https:\/\/doi.org\/10.1111\/jsr.14399.","DOI":"10.1111\/jsr.14399"},{"key":"10.1016\/j.sleep.2026.108792_bib140","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.sleep.2026.108792_bib141","article-title":"A preliminary report on the effects of daridorexant in patients with comorbid insomnia and substance use disorders","volume":"18","author":"Di Nicola","year":"2025","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.sleep.2026.108792_bib142","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14196","article-title":"Early experience with the new DORA daridorexant in patients with insomnia disorder and comorbid mental disturbances: results of a naturalistic study with 3 months follow-up","volume":"33","author":"Palagini","year":"2024","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2026.108792_bib143","first-page":"33","article-title":"Effect of graduated drug therapy for moderate-to-severe chronic insomnia on the severity of disease: an observational study in Germany","volume":"21","author":"Boer","year":"2025","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib144","first-page":"3443","article-title":"Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study","volume":"45","author":"Fernandes","year":"2024","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"10.1016\/j.sleep.2026.108792_bib145","first-page":"e85","article-title":"Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment","volume":"2","author":"Hayashi","year":"2023","journal-title":"PCN Rep Psychiatry Clin Neurosci"},{"key":"10.1016\/j.sleep.2026.108792_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1495965","article-title":"Efficacy and safety of Lemborexant in treating adult patients with insomnia in China: a single-center, retrospective observational study","volume":"16","author":"Jian","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.sleep.2026.108792_bib147","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211039098","article-title":"The effect of lemborexant for insomnia disorder","volume":"9","author":"Suzuki","year":"2021","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.sleep.2026.108792_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleepx.2023.100098","article-title":"Transitioning insomnia patients from zolpidem to lemborexant: a multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy","volume":"7","author":"Ahmad","year":"2024","journal-title":"Sleep Med X"},{"key":"10.1016\/j.sleep.2026.108792_bib149","first-page":"1753","article-title":"Switching to lemborexant for the management of insomnia in mental disorders: the SLIM study","volume":"19","author":"Horikoshi","year":"2023","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleepx.2023.100070","article-title":"Safety and real-world efficacy of lemborexant in the treatment of comorbid insomnia","volume":"5","author":"Katsuta","year":"2023","journal-title":"Sleep Med X"},{"key":"10.1016\/j.sleep.2026.108792_bib151","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2868","article-title":"Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant","volume":"38","author":"Okino","year":"2023","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib152","first-page":"603","article-title":"A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists","volume":"20","author":"Tachibana","year":"2024","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sleep.2026.108792_bib153","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/14656566.2024.2392018","article-title":"Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan","volume":"25","author":"Tanaka-Mizuno","year":"2024","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.sleep.2026.108792_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1436405","article-title":"Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sleep.2026.108792_bib156","first-page":"1","article-title":"Safety of dual orexin receptor antagonists: a real-world pharmacovigilance study","author":"Sun","year":"2025","journal-title":"Expet Opin Drug Saf"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:39:53Z","timestamp":1776159593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945726000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":154,"alternative-id":["S1389945726000304"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2026.108792","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Dual Orexin Receptor Antagonists on sleep: a systematic review and pairwise meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2026.108792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108792"}}